In this regard, I'd note especially that Amgen year in and year out, pays nearly no federal corporate income taxes (See Note 6 on page F-21), yet it just laid off 300 US workers on the commercial teams, last week (saying it cannot afford them, while being wildly profitable -- and immensely cash flow positive, for all its global shareholders, this year and next, to be certain). This is no company struggling under massive debt, nor facing dying markets. So. . . what's fair about that, I'd ask?
[We will have more on this, in the Pfizer installment (on patent chicanery), as well.] But here on a State of the Union night, tonight, albeit slightly delayed -- is what Merck lobbied about:
. . .H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19 Lower Costs, More Cures Act of 2021; H.R. 1550, PREVENT HPV Cancers Act of 2021; H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021; H.R. 3173, Improving Seniors Timely Access to Care Act of 2021; H.R. 3655, Vaccine Injury Compensation Modernization Act of 2021; H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021; H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021; H.R. 5416, Give Kids a Chance Act; H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act; H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act; H.R. 6963, Accelerated Approval Integrity Act of 2022; H.R. 7559, Prescription Information Modernization Act of 2022; H.R. 7667, Food and Drug Amendments of 2022; S. 1435, Affordable Prescriptions for Patients Act of 2021; S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019; S. 2774, Pride in Patent Ownership Act; S. 2891, Restoring the America Invents Act; S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019; S. 1895 (116th Congress) Lower Health Care Costs Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; S. 4760, (116th Congress) The PASTEUR Act
Issues relating to: 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms -- international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Prescription Drug User Fees Act (P.L. 102-571); Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Animal Drug User Fee Act (P.L. 108-130); Prescription drug cost-sharing; Accelerated approval reform; Food and Drug Administration Safety and Landmark Advancements (FDASLA); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; Animal Health Technology Issues; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023; Vaccine Injury Compensation Program. . . .
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, provisions related to Medicare Part B; H.R. 2716, Consolidated Appropriations Act; 2023 provisions relating to Medicare Part D emergency use authorization coverage; H.R. 5376, Build Back Better Act; S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019
Issues relating to: Medicaid; Medicare; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; Prior authorization process under Medicare Advantage plans; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; Prior Authorization under Medicare Advantage Plans; FY-2023 Budget and Appropriations Legislation. . . .
H.R. 5376, Inflation Reduction Act of 2022, including provisions relating to budget reconciliation tax provisions
Issues related to: Tax reform and tax policy, generally; Tax Cuts and Jobs Act of 2017 (P.L. 115-97); Tax provisions of Budget Reconciliation. . . .
Now you know -- onward, smiling a sardonic smile, tonight.
नमस्ते
No comments:
Post a Comment